DUOSTIM
Drug2 consecutive stimulations by Fertistartkit® on the same cycle
Other names: Same monthly cycle
NCT Number: NCT03803228
During ovarian stimulation, all the follicles grow under the action of FSH, only the selected follicles and with the faster growth are taken. However during this stimulation, other smaller follicles are also recruited and sensitized, which may increase the selection of follicles available on the follicular wave following. In patients with weak reserve this potentiation has a great interest, and the sequence of 2 stimulations on the same cycle could make it possible to obtain a larger number of oocytes and embryos, thus giving a better chance of delivery than on 2 distinct cycles of stimulation. However, this is preliminary data that needs to be confirmed with a randomized controlled trial. In this population of poor prognosis, the use of FSH-associated LH activity may optimize the ovarian response to stimulation, particularly the combination containing placental HCG (Fertistartkit®) that obtaining a slightly higher number of oocytes than highly purified HMG (Menopur®).
Looking for future studies?
Notify Me20 year–41 year
Female
Interventional
Phase 3
Polyclinique Jean Villar, Bruges, France
Ovarian stimulation is an essential prerequisite for any in vitro fertilization attempt (IVF) to optimize the chances of delivery per cycle. These depend in the first place on the age of the patients and secondly on the number of oocytes collected. There is a strong correlation between these two factors, the ovarian reserve diminishing with age. In older patients or patients with decreased reserve, however, the number of oocytes collected remains a prognostic factor for the chances of delivery.
At the present time, there is no validated intervention that would bring a significant interest on the number of oocytes obtained in the group of bad responder patients. However, it is a very heterogeneous population whose definition has been proposed only recently, the Bologna criteria and questioned by a new proposal from the Poseidon group. The latter is more focused on the prognosis of success, differentiating patients with a diminished reserve (count of antral follicles CFA <5 and / or AMH <1.2 ng / ml) from those with an "unexpected" bad response. As the profiles are better defined, it is easier to determine the impact of a strategy in a specific group.
Recent clarifications on the ovarian cycle and folliculogenesis have shown that several waves of follicular development coexist on the same cycle and that it is perfectly possible to obtain a follicular development with a luteal phase equivalent oocyte quality, compared to conventional stimulations performed in the follicular phase. The main constraint of luteal phase stimulation is the lack of possibility of fresh transfer due to non-synchronization with the endometrium. This constraint is today secondary given the evolution of conservation techniques with the development of embryonic and oocyte vitrification.
On the other hand, there is a differential dependence of FSH follicles, their sensitivity depending on the number of FSH receptors and their duration of exposure to FSH. During ovarian stimulation, all the follicles grow under the action of FSH, only the selected follicles and with the faster growth are taken. However during this stimulation, other smaller follicles are also recruited and sensitized, which may increase the selection of follicles available on the follicular wave following. In patients with weak reserve this potentiation has a great interest, and the sequence of 2 stimulations on the same cycle could make it possible to obtain a larger number of oocytes and embryos, thus giving a better chance of delivery than on 2 distinct cycles of stimulation. However, this is preliminary data that needs to be confirmed with a randomized controlled trial. In this population of poor prognosis, the use of FSH-associated LH activity may optimize the ovarian response to stimulation, particularly the combination containing placental HCG (Fertistartkit®) that obtaining a slightly higher number of oocytes than highly purified HMG (Menopur®).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 consecutive stimulations by Fertistartkit® on the same cycle
Other names: Same monthly cycle
2 stimulations by Fertistartkit® performed on 2 different cycles
Other names: Two different menstrual cycles
Time frame: up to 60 days
cumulative number of oocytes on 2 punctures
Time frame: up to 60 days
cumulative number of follicles> 14mm
Time frame: up to 60 days
cumulative number of oocytes in metaphase II
Time frame: 1 month
cumulative number of embryos obtained
Time frame: up to 60 days
number of embryos transferred
Time frame: 1.5 month
number of frozen embryos
Time frame: up to 60 days
cumulative total dose of FSH
Time frame: up to 20 days
the number of stimulation days
Time frame: up to 20 days
estradiol level
Time frame: up to 20 days
LH level
Time frame: up to 20 days
progesterone level
Time frame: 3 months
cancellation or no transfer rate
Time frame: up to 9 months
cumulative rates of early pregnancy (HCG> 100) and ultrasound (6-7SA)
Time frame: up to 9 months
number of beginner pregnancy in each groups
Time frame: up to 9 months
cumulative cost of 2 attempts including frozen embryo transfers (treatments, consultations, MPA laboratory and monitoring exams)
Time frame: up to 9 months
reported side effects
Centre Hospitalier Intercommunal Creteil
Other
Comparison of the Cumulative Number of Oocytes Obtained With 2 Controlled Ovarian Hyperstimulations (COH) Within the Same Cycle With FertistartKit® (DUOSTIM) Versus 2 Conventional COH in Poor Ovarian Responders Undergoing IVF. Bistim Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07464275
Fertility Disorders, Genital Diseases
Toronto, Ontario, Canada
View Trial DetailsNCT05271981
Connective Tissue Diseases, Fertility Disorders
Paris, France
View Trial DetailsNCT03085433
Embryo Quality, Fertility Disorders
San Francisco, California, United States
View Trial DetailsNCT06128395
Fertility Disorders
Montreal, Quebec, Canada
View Trial Details